WCM
NVCR icon

Washington Capital Management’s NovoCure NVCR Stock Holding History

Washington Capital Management’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-32,400
Closed -$353K – 120
2026
Q1 		$353K Buy
32,400
+1,400
+5% +$17.5K 0.3% 90
2025
Q4 		$401K Hold
31,000
– – 0.33% 86
2025
Q3 		$401K Buy
31,000
+10,000
+48% +$134K 0.29% 95
2025
Q2 		$374K Buy
+21,000
New +$366K 0.28% 99

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
QCM
Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return

Washington Capital Management's NVCR Position: Q2 2026 in Review

Washington Capital Management sold out of NovoCure (NVCR) in Q2 2026, closing a stake of 32,400 shares — an estimated $353K sold.

Washington Capital Management first reported a position in NVCR in Q2 2025 and held it in 4 quarters. The position peaked at $401K in Q4 2025. 218 funds tracked by Wall St. Rank hold NVCR as of Q2 2026.

  • Washington Capital Management reported no remaining NovoCure position as of Q2 2026 after selling out during the quarter.
  • Washington Capital Management sold 32,400 NovoCure shares in Q2 2026, an estimated $353K.
  • Washington Capital Management first reported a position in NovoCure in Q2 2025 and held it in 4 quarters.
  • Washington Capital Management's NovoCure position peaked at $401K in Q4 2025.
  • 218 funds tracked by Wall St. Rank held NovoCure as of Q2 2026.

Based on Washington Capital Management's 13F filing for Q2 2026, filed 21 Jul 2026.